GlobeNewswire·Feb 26, 2026, 8:30 AM ET

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

RNXT

RenovoRx, Inc. (NASDAQ: RNXT) announced the acceptance of a clinical data abstract by Moffitt Cancer Center for presentation at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting.
The meeting is scheduled for April 11-15, 2026, in Toronto, Ontario, with the specific abstract presentation set for Monday, April 13, 2026, from 4:45-5:45 PM ET.
The abstract, titled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer," explores the hypothesis that RenovoRx's TAMP therapy platform can improve treatment outcomes for locally advanced pancreatic cancer by addressing poor vascularity.
Dr. Mustafa Al-Roubaie, an Interventional Radiologist at Moffitt Cancer Center & member of RenovoRx's Medical Advisory Board, led the submission which evaluates metabolic imaging (FDG PET/CT) for assessing therapeutic activity in patients with refractory disease.
RenovoCath, an FDA-cleared drug-delivery device, is being commercialized as a stand-alone product; the company reported approximately $900,000 in revenues from RenovoCath sales during the first nine months of 2025.
RenovoRx is currently evaluating its IAG product candidate (intra-arterial gemcitabine delivered via RenovoCath) in the Phase III TIGeR-PaC trial, which holds Orphan Drug Designation for pancreatic & bile duct cancer.
The company is expanding its customer base to include high-volume National Cancer Institute-designated centers while exploring further revenue-generating activities through partnerships or direct sales.